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Because of the growing interest over the past decade in primary
central nervous system lymphoma (PCNSL), more information is
now available on optimal primary treatment, which has made a
significant impact on survival. Recent prospective series (De
Angelis et al, 1992; Glass et al, 1994, 1996) and review studies
(Jellinger and Paulus, 1992; Fine and Mayer, 1993; Ferreri et al,
1995a; Reni et al, 1997) have shown that the combination of
chemotherapy (CHT) containing high-dose methotrexate and radio-
therapy (RT), delivering more than 40 Gy to the whole brain, plus a
boost that exceeds 50 Gy to the tumour bed doubles survival
compared with RT alone. Despite the high complete remission rate
achieved with first-line therapy, 35—60% of patients submitted to
combined treatment modality (CTM) relapse and die of lymphoma
within a few months from recurrence (De Angelis et al, 1992; Glass
et al, 1994; Selch et al, 1994; Sarazin et al, 1995). Most patients
presenting progressive or relapsed disease did not receive additional
treatment and, unlike extraneural non-Hodgkin￿s lymphoma (NHL),
the impact of salvage therapy on survival and quality of life remains
unclear because of the lack of reports focusing on this issue. The
present paper analyses prognostic factors and the impact on survival
of second-line therapy in PCNSL by reviewing published series
reporting the therapeutic results for first-line treatment.
MATERIALS AND METHODS
All papers on immunocompetent patients with PCNSL published in
English literature were considered. Complete data of disease-free
survival (DFS), overall survival (OS) and management of recurrent
or progressive disease after first-line treatment were available for
each patient in 24 out of 59 considered series (Sagerman et al,
1967; Rampen et al, 1980; Letendre et al, 1982; Gonzalez and
Schuster-Uitterhoeve, 1983; Mendenhall et al, 1983; Loeffler et al,
1985; Woodman et al, 1985; Di Marco et al, 1986; Murray et al,
1986; Vakili et al, 1986; Yasunaga et al, 1986; McLaughlin et al,
1988; Shibamoto et al, 1990; Uematsu et al, 1992; Watne et al,
1992; Boiardi et al, 1993; Glass et al, 1994, 1996; Lachance et al,
1994; Ling et al, 1994; Selch et al, 1994; Ferreri et al, 1995b;
Sarazin et al, 1995; Freilich et al, 1996). Three hundred and fifty-
five cases were reported in the analysed series: 334 patients
received RT, CHT or CTM as first-line treatment, whereas 21
patients were not submitted to any therapy after diagnosis. The
present review focuses on the 173 patients presenting recurrent or
progressive disease after first-line therapy, whereas 161 were
excluded from analysis because they were either relapse-free, lost
to follow-up, dead without evidence of disease or dead of treatment
toxicity at the time of report.
Age at failure, time to relapse and type of failure are summa-
rized in Table 1. Age was reported in 160 cases: 91 (56.8%) were
†60 years old and 69 (43.2%) >60 years. Performance status at
treatment failure was never available. Failure consisted of relapse
after an initial objective response in 120 patients, and progressive
disease in 53 patients. The interval between primary diagnosis and
relapse was defined as time to relapse (TTR), whereas the interval
between failure and death was defined as time to death (TTD).
Relapse was considered ￿early￿ if it occurred at 12 months or less
(n = 68) and ￿late￿ if it occurred thereafter (n = 52). Fifty-nine
cases were submitted to salvage therapy at time of relapse (n = 52)
or progression (n = 7), whereas 114 received no treatment at time
of relapse (n = 68) or progression (n = 46). Second-line treatment
varied; 26 different therapeutic schedules were used in 55 cases,
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whereas the CHT regimen was not reported in the remaining four
patients. At time of failure, 36 patients were treated with RT alone
(n = 24) or in combination with CHT (n = 12), whereas 23 patients
underwent CHT as exclusive salvage treatment.
TTR and TTD curves were generated using the Kaplan—Meier
method (Kaplan and Meier, 1958). Impact on TTD of age (†60
years vs >60 years), type of failure (recurrent vs progressive
disease), TTR (early vs late relapse), second-line treatment (yes vs
no) and use of RT (yes vs no) was evaluated by comparing the
TTD curves by the log-rank test (Peto and Pike, 1973). A multi-
variate analysis by the Cox proportional hazard model (Cox, 1972)
was performed on the entire patient group to evaluate the indepen-
dent role of age, type of failure and retreatment. This analysis,
however, did not assess the predictive value of TTR due to the
inclusion of patients with progressive disease. A multivariate
analysis on TTR, age and salvage treatment, limited to relapsed
patients, was also performed.
RESULTS
The predictive value of age on TTD was analysed. Median TTD
was 6 months for patients †60 years and 3 months for >60 years
(P = 0.09).
TTD of 120 patientss with relapsing disease was compared with
TTD of 53 patients with progressive disease. The median age in the
two groups overlapped (59 and 58 years respectively). Median TTD
was 5 and 3 months respectively (P = 0.002) (Figure 1). Median
TTR for the entire group of 120 relapsed patients was 10 months.
Early relapse occurred in 68 patients, with a median age of 60 years
(range 1—89) and a median TTD of 4 months. Fifty-two patients had
late relapse. Their median age was 55 years (range 14—76), and the
median TTD was 10 months. The difference between TTD curves
was statistically significant (P = 0.005) (Figure 2).
The median age of patients receiving and of those not receiving
second-line therapy was 55 and 59 years respectively. Median
TTD for patients submitted to salvage therapy (n = 59) and
untreated patients (n = 114) was 14 and 2 months respectively
(P < 0.00001) (Figure 3). For retreated patients, 1- and 3-year
actuarial TTD were 53% and 15%. Two patients were still alive
5 years after failure. Meanwhile, 1- and 3-year actuarial TTD was
14% and 0% for untreated patients.
Salvage therapy significantly improved survival in each patient
subset based on age groups, on time to relapse or on type of failure
(P < 0.001 in each analysis). Inclusion of RT in second-line treat-
ment schedules, either in combination with CHT or alone, raised
the mTTD to 16.5 months compared with the 10 months obtained
with chemotherapy alone (P = 0.03) (Figure 4).
Table 1 Age, time to relapse (TTR) and type of failure for patients
submitted or not to salvage therapy
Type of
Retreated
failure TTR (months) Age (years)
patients n Rel PD <12 ³12 ≤60 >60
Yes 59 52 7 29 23 36 15
N o 1 1 4 6 8 4 63 9 2 95 5 5 4
Rel, relapse; PD, progressive disease.
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Figure 1 Time to death curves according to the type of failure after first-line
treatment
Figure 2 Time to death curves according to the duration of time to relapse
after first-line treatment
Figure 3 Comparison of time to death curves for retreated (……) or
untreated (¾) patients532 M Reni et al
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Results of multivariate analyses by the Cox proportional hazard
model performed on the entire study group (n = 160) and on
relapsed patients (n = 110) to evaluate age, TTR, type of failure
and salvage therapy showed that only salvage therapy and TTR
had prognostic value (relative risk  =  3.5 and 0.57; P = 0.000001
and 0.01 respectively).
DISCUSSION
Relapse of extraneural NHL had been considered fatal until the
advent of high-dose chemotherapy followed by autologous or allo-
genic bone marrow or peripheral blood stem cell transplantation.
However, only a subset of relapsed patients can be selected for
such life-threatening treatment, whereas most patients undergo
standard salvage chemotherapy, achieving an overall response rate
of 45—85%, with 20—45% complete response (CR), a median
survival of 8—14 months and a 3-year survival rate of 20—30%
(Velasquez et al, 1994; Rodriguez et al, 1995). About one-half of
immunocompetent patients with PCNSL, achieving CR with
primary treatment, relapse, whereas 10—15% present refractory
disease (De Angelis et al, 1992; Glass et al, 1996). Furthermore,
half of the 5-year survivors relapse after 5—13 years from diagnosis
(Murray et al, 1986). Prognosis for both recurrent and progressive
PCNSL is poor, and most patients die within 2—4 months because
of neurological deterioration (Pollack et al, 1989; De Angelis et al,
1992). Brain relapse is the overwhelming cause of failure in
PCNSL. The disease, which is responsible for progressive neuro-
logical deficits and a poor quality of life, is invariably fatal. The
role of salvage therapy for PCNSL has not yet been defined
because there is no report on this issue, and more than half of the
papers on first-line treatment do not report data on TTR, overall
survival and management of recurrent or refractory patients.
However, some anecdotal observations have suggested that
second-line treatment could achieve a further remission and conse-
quent symptomatic improvement. Neuwelt et al (1991) retreated
nine out of ten recurrent PCNSL: four were still alive and disease-
free at time of report. Pollack et al (1989) observed a statistically
significant survival improvement in ten patients receiving second-
line therapy compared with five untreated cases (P < 0.05). Four
retreated patients were still alive 6—48 months after recurrence. In
contrast, a few authors reported poor results with salvage therapy
(Soci￿ et al, 1990; Nelson et al, 1992; Krogh-Jensen et al, 1994).
However, the number of patients was small and data not complete.
This review attempted to identify the prognostic value of some
variables such as age at relapse, time to relapse and type of failure,
and the impact on survival of salvage treatment at recurrence or
progression. Both univariate and multivariate analyses showed
that, unlike PCNSL at first diagnosis, age at failure had no predic-
tive value on survival, and that early relapse led to a worse
outcome than late relapse.
It is difficult to interpret the results of the analysis of type of
failure as a prognostic factor. Univariate analysis showed that
patients with recurrent PCNSL survived significantly longer than
those with refractory disease. However, this result could be biased
because of the prevalence of untreated patients in the group with
progressive disease (46 out of 53), whereas 52 out of 120 relapsed
patients were retreated. Alternatively, multivariate analysis did not
show any difference in relative risk between recurrent and progres-
sive disease. This unexpected result could depend on a diverse
definition of refractory and recurrent disease in the papers consid-
ered, with this diversity probably leading to the inclusion of some
patients with progressive disease in the relapse group.
Salvage therapy was the variable with the highest predictive
value of TTD. The significant improvement of outcome in
retreated patients was evident in both univariate and multivariate
analyses. However, the lack of performance status (PS) data could
constitute a bias because patients with lower PS are rarely
proposed for salvage therapy. In an attempt to exclude this bias,
the comparison between TTD curves of retreated and untreated
patients was also carried out by excluding, only in the latter group,
patients with TTD †2 months, who probably had worse PS. The
log-rank test again showed a statistically significant difference
between curves (P = 0.01, data not shown).
The present review suggests the efficacy of salvage therapy in
terms of survival improvement for patients grouped on the basis of
type of failure, TTR and age. Outcome of salvage therapy was
probably underestimated because of the inclusion, in the retreated
group, of patients receiving ineffective CHT regimens. The high
rate of second CR probably had an impact on the retreated
patients￿ quality of life, even though no author studied this issue
thoroughly. Because of the many different types of first- and
second-line treatment used in the analysed papers, no conclusion
could be drawn concerning optimal schedule. Cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP) regimen at recur-
rence obtained poorer results than drugs that permeate the
blood—brain barrier (BBB) (De Angelis et al, 1992). In the papers
considered, all three patients receiving CHOP at failure died
within 8 months. Also as first-line therapy, CHOP or cyclo-
phosphamide, doxorubicin, vincristine and dexamethasone
(CHOD) regimens were ineffective (Lachance et al, 1994; O￿Neill
et al, 1995; Bessell et al, 1996; Glass et al, 1996; Schultz et al,
1996). A salvage treatment schedule should include drugs that can
cross the BBB and, in particular, agents with some efficacy as
primary treatment, such as high-dose methotrexate, cytarabine,
vincristine, procarbazine or nitrosureas (Kawakami et al, 1985; Di
Marco et al, 1986; McLaughlin et al, 1988; Chamberlain and
Levin, 1990; De Angelis et al, 1992; Boiardi et al, 1993; Glass et
al, 1994; Bessel et al, 1996; Freilich et al, 1996; Reni et al, 1997).
In the current review, median survival and TTD were better in
patients receiving irradiation with or without CHT at failure than
in patients who underwent CHT alone. Twenty-five out of 36 cases
in the first group had been previously irradiated. The heterogeneity
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Figure 4 Comparison of time to death curves for patients receiving RT with
or without CHT (¾) or CHT alone (……) as second-line treatmentof both first- and second-line RT doses and fields does not allow us
to give precise indications. However, RT most probably has a role
in salvage treatment. To better define optimal management of
relapsing or progressive PCNSL, reporting of single-centre experi-
ence should be encouraged. Furthermore, the description of
second-line therapy in series of primary treatment of PCNSL
appears mandatory because of the statistically significant impact
on outcome.
In conclusion, salvage therapy in recurrent or progressive
PCNSL appears worthwhile because it achieves an increment of
TTD compared with untreated patients. It also apparently reduces
the intensity of neurological symptoms related to failure, thus
improving the quality of life. Further improvement of outcome in
PCNSL could derive from a better definition of an optimal treat-
ment schedule for both the first- and the second-line therapy.
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